Real-world impact of incretin meds on cancer risk in adults with diabetes
Official title: Real-World Impact of Incretin Mimetics on Cancer Risk Using Targeted Learning
Funded at Kaiser Foundation Research Institute · NIH-11385145 · Data updated 2026-11-12
This study looks at how long-term use of GLP-1 receptor agonists for adults with type 2 diabetes or obesity might affect their cancer risk, using real-world medical data.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kaiser Foundation Research Institute NIH-funded |
| Lab location | 1 site (Oakland, UNITED STATES) |
| Project start | August 1, 2026 |
| Project end | July 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $733,410 |
| NIH project number | 1R01CA305920-01A1 |
| Project ID | NIH-11385145 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults aged 21 and older with obesity and/or type 2 diabetes who are active in Kaiser Permanente databases and have documented use of incretin mimetics.
✕Less likely to help
Patients not using incretin mimetics or without sufficient longitudinal data may not benefit from the findings.
What this research studies
Researchers will compare people using incretin mimetics over time to those with similar health profiles to see if sustained use changes cancer risk, using advanced statistical methods and machine learning to mimic a controlled trial. They will focus on data from Kaiser Permanente to track adherence, weight, blood sugar, and cancer outcomes. The study aims to provide clearer answers using per-protocol analyses that reflect real-world medication use and adherence.
Why it matters
Potential benefit: If successful, findings could guide safer, more effective use of incretin mimetics and inform cancer risk counseling for patients taking these medicines.
How similar studies have gone: Prior observational studies show mixed results; this study uses robust target trial emulation to address prior limitations.
Where this research is happening
-
Kaiser Foundation Research Institute
Oakland, United States Active
Researchers
- Principal investigator: Feliciano, Elizabeth Marjorie Cespedes — Kaiser Foundation Research Institute
- Study coordinator: Feliciano, Elizabeth Marjorie Cespedes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.